Open innovation (OI) is becoming a popular R&D
management strategy in pharmaceuticals. In this study, we
performed a comprehensive data collection on drug candidate
acquisition, that has been the major OI mode during the drug
development phase, in the Japanese pharmaceutical industry for
the past 30 years. Our empirical analysis revealed that the
acquisition of drug candidates has been widely conducted
(accounting for a quarter of all newly developed compounds),
and has contributed to more than half of launched products.
Surprisingly, the acquisition of drug candidates has remained
flat for the past 20 years; it has not increased in recent years
despite the advocacy of OI. Acquisition at the preclinical stage
was prevalent in the 1980s, and then late-stage acquisition
started to increase and has dominated in recent years. There was
no significant difference in therapeutic area distribution
between in-house and outside-origin projects, suggesting that
drug candidate acquisition was utilized mainly to reinforce
internal R&D. Our findings can serve as a basis for discussion
on the future direction of drug candidate acquisition in the
Japanese pharmaceutical industry.
各種検索
サポート
ヘルプ